Alnylam Pharmaceuticals Inc (ALNY)vsNiagen Bioscience, Inc. (NAGE)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
NAGE
Niagen Bioscience, Inc.
$4.52
-0.44%
HEALTHCARE · Cap: $373.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 2770% more annual revenue ($3.71B vs $129.42M). NAGE leads profitability with a 13.4% profit margin vs 8.5%. NAGE trades at a lower P/E of 23.3x. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
NAGE
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-275.7%
Fair Value
$1.36
Current Price
$4.52
$3.16 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Every $100 of equity generates 28 in profit
16.2% revenue growth
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Smaller company, higher risk/reward
Earnings declined 41.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : NAGE
The strongest argument for NAGE centers on Return on Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : NAGE
The primary concerns for NAGE are Market Cap, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while NAGE is a growth play — different risk/reward profiles.
NAGE carries more volatility with a beta of 2.23 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 45/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Niagen Bioscience, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?